

Novel and Emerging Therapeutic Strategies in the Management of Select B-Cell Lymphomas

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Results of the Phase III CLL14 study included which of the following progression-free survival (PFS) outcomes with venetoclax/obinutuzumab compared to chlorambucil/obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL)?**
 - No statistical difference between the regimens
 - Significant improvement with venetoclax/obinutuzumab in the overall patient population
 - Significant improvement with venetoclax/obinutuzumab for patients with no cytogenetic abnormalities only
- Which of the following CD19-directed chimeric antigen receptor T-cell products was assessed in the pivotal JULIET study and approved by the FDA for patients with relapsed diffuse large B-cell lymphoma or transformed lymphoma?**
 - Axicabtagene ciloleucel
 - Lisocabtagene maraleucel
 - Tisagenlecleucel
- Results from the Phase III ECOG-ACRIN E1912 study, comparing ibrutinib/rituximab followed by maintenance ibrutinib to FCR (fludarabine/cyclophosphamide/rituximab) for previously untreated CLL, demonstrated a statistically significant improvement in PFS with ibrutinib/rituximab in which patient subgroup?**
 - Patients with IGHV mutation
 - Patients with no IGHV mutation
- What was reported regarding the overall and complete response rates with KTE-X19 for patients with relapsed/refractory mantle cell lymphoma in the Phase II ZUMA-2 trial?**
 - High overall response rate with more than 50% complete responses
 - 50% overall response rate but no complete responses
 - Low overall response rate with no complete responses
- Based on clinical efficacy data from the Phase III ECHELON-1 study, which of the following regimens would be most appropriate for a patient with previously untreated Stage IV classical Hodgkin lymphoma?**
 - Brentuximab vedotin monotherapy
 - Brentuximab vedotin and ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
 - Brentuximab vedotin and AVD